Canada As the President of Innovative Medicines Canada, Pamela Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need when they need them. In her first article for PharmaBoardroom, Pamela calls for the regular assessment…

Canada The research areas in which Canada has the potential to excel are numerous, one being the world of genomics. The stem cell itself having been discovered in Canada, Marc LePage, president and CEO of Genome Canada, identifies great potential to attract more fundamental research into that domain in the future.…

Canada PharmaBoardroom’s list of personalities whose voices, opinions and decisions matter in Canadian pharma’s industry, regulatory affairs, reimbursement and pricing.     The Honourable Ginette Petitpas Taylor Minister of Health  The Honourable Ginette Petitpas Taylor was elected in October 2015 as a Member of Parliament in the riding of Moncton–Riverview–Dieppe. Ms…

Pharmacy Meghann Chilcott, Chief Technology/Marketing Officer at Benzer Pharmacy looks at current pharmaceutical service trends that aim to create a more perfect union among technology, medication delivery and patient care for independent pharmacists. The move toward automation is reducing the complexity faced by medical coders, with software acting as the go-between, providing…

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…

Opinion Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P. Morgan’s 2019 Health Care Investor Conference, one of the biggest events in the life sciences calendar and a fantastic indicator of what is to come in healthcare for the year ahead. Here, Crean gives us the inside scoop. …

Opinion Carla Smith is a healthcare thought leader with nearly 30 years’ experience. She champions transformational strategy, governance, and policy in the health sector, particularly in the areas of digital health and health IT. In this article, Ms Smith discusses the massive potential of digital therapeutics in helping patients manage their…

Opinion After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and to accelerate the path to better therapies. Here Monica discusses the incredibly low rate of treatment options for…

Bristol-Meyers Squibb Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share…

USA Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) weighs in on the issue of drug shortages in America.    An uncertain environment for generic manufacturers imperils the sustainability of patient access to low-cost generic medicines.   The unavailability of prescription medicines can cause physical suffering,…

Mexico David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies.   In Mexico, approximately 15 percent of patients treated with therapies for rare diseases, dismiss the concept of adherence to treatments. In Latin American Countries such as Mexico, keeping…

Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here Thompson discusses the need for stronger public-private sector alliances in the push towards universal…